NASDAQ:EYPTEyepoint Pharmaceuticals Stock Price, Forecast & News

Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYPT shares have decreased by 18.1% and is now trading at $0.86. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The company earned $7.49 million during the quarter, compared to analyst estimates of $6.95 million. Eyepoint Pharmaceuticals had a negative return on equity of 286.40% and a negative net margin of 196.31%. View Eyepoint Pharmaceuticals' earnings history.

4 analysts have issued 12 month price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $1.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' stock price to reach $3.63 in the next twelve months. This suggests a possible upside of 321.5% from the stock's current price. View analysts' price targets for Eyepoint Pharmaceuticals.

Press coverage about EYPT stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutEyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 2,820,000 shares, a decline of 8.4% from the March 31st total of 3,080,000 shares. Based on an average trading volume of 818,100 shares, the days-to-cover ratio is currently 3.4 days. Approximately 3.5% of the company's shares are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyepoint Pharmaceuticals include Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO), Horiba (HRIBF), PositiveID (PSID) and Scientific Industries (SCND). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL).

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Eyepoint Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.06%), Franklin Resources Inc. (3.32%), State Street Corp (0.90%), Geode Capital Management LLC (0.72%), Essex Investment Management Co. LLC (0.51%) and Integrated Advisors Network LLC (0.38%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View institutional ownership trends for Eyepoint Pharmaceuticals.

EYPT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Essex Investment Management Co. LLC, and UBS Group AG. View insider buying and selling activity for Eyepoint Pharmaceuticals.

EYPT stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Raymond James Financial Services Advisors Inc., Integrated Advisors Network LLC, Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Two Sigma Investments LP, and BlackRock Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis, and Nancy Lurker. View insider buying and selling activity for Eyepoint Pharmaceuticals.

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EYPT stock can currently be purchased for approximately $0.86.

Eyepoint Pharmaceuticals has a market capitalization of $107.28 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.

The official website for Eyepoint Pharmaceuticals is www.eyepointpharma.com.

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]